This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the use of Amtagvi (lifileucel) in previously treated melanoma
Ticker(s): IOVAWho's the expert?
Institution: Fox Chase Cancer Center
- Vice chair of the department of hematology/oncology at Fox Chase, Director of the Early Clinical Drug Development Phase I Program and Co-Director of the Melanoma and Skin Cancer Program.
- Treats 40 new patients with melanoma per year & 60 in follow-up.
- Sits on the NCCN melanoma guidelines panel, has written, developed and run many investigator-initiated trials, and has served as the PI on more than 50 trials.
Interview GoalDiscuss early adoption so far of Amtagvi, thoughts on how commercialization might look
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
